An observational study in Mild Cognitive Impairment (MCI), Virtual Reality and Eye Movement Disorder, sponsored by National Cheng-Kung University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by National Cheng-Kung University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Cognitive Dysfunction with a site in Taiwan — 24 open to participants now, 29 under way, 3 of them phase 3. Cognitive Dysfunction · Taiwan.
Among the 111 studies in Cognitive Dysfunction with a site in Taiwan, this one is the 8th largest by planned enrollment of the 17 observational ones that give a count, is one of 5 that started in 2026, is one of 17 observational ones, reaches primary completion later than 25 of the 28 other live ones, and was the 108th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →24 of the 111 studies in Cognitive Dysfunction with a site in Taiwan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Taiwan, United States, Japan and 1 more country
Ages 55–85
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Taiwan, Australia, Austria and 14 more countries
Ages 18+
Cheng-Hsin General Hospital · Sites in Taiwan
Ages 65–90
National Sun Yat-sen University · Sites in Taiwan
Ages 65+ · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 50+ · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 192 is above the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 62 across the 94 interventional studies, 192 across the 17 observational. Of the 60 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 111 have an industry lead sponsor. The 10 most frequent:
National Cheng-Kung University Hospital is the lead sponsor of 280 studies on the registry; 71 are open to participants now.
National Cheng-Kung University Hospital has 3 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
5 of the studies in Cognitive Dysfunction with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07358598National Sun Yat-sen UniversityEye Movement Parameters and Cognitive Functions in Older Adults | 2026-12-31 |
| NCT05830903National Taiwan University HospitalDevelop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques | 2026-12-31 |
| NCT06902181China Medical University HospitalObservation of Inhalation of CXMCI-01 Essential Oil on Patients With Mild Cognitive Impairment | 2027-02 |
| NCT06467539Chang Gung Memorial HospitalNovel Augmentation of DAOIB and Antioxidant for Early Dementia | 2027-05 |
| NCT05448768Chang Gung Memorial HospitalCognitive Effects and Potential Mechanisms of TBS in Subjects With MCI | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 111 studies in Cognitive Dysfunction with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Driving ability in older adults is essential for independent mobility and social participation, yet declines under high cognitive load or distraction often lead to visual attention failures such as "look-but-fail-to-see," increasing crash risk. Older adults and individuals with mild cognitive impairment (MCI) show impairments in visual attention, executive control, and visuomotor integration, which are not adequately captured by conventional assessments. Virtual reality (VR) integrated with eye-tracking and upper-limb motion analysis enables ecologically valid simulation of driving scenarios and precise quantification of visuomotor behavior. However, current studies are limited by single-scenario designs, unimodal AI models, and insufficient integration of action-related data.
This study proposes a multi-phase framework: Year 1 develops an eye-movement-based AI model for MCI identification; Year 2 integrates multimodal data in VR driving tasks; and Year 3 establishes an explainable AI system with longitudinal validation. The study aims to advance cognitive assessment and develop a digital tool for early MCI detection and driving risk prediction.
Driving ability in older adults is closely associated with independent mobility and social participation. However, under conditions of high cognitive load or distraction, visual attention failures-such as the "look-but-fail-to-see" phenomenon-frequently occur and substantially increase crash risk. Previous studies have demonstrated that older adults and individuals with mild cognitive impairment (MCI) exhibit declines in visual attention allocation, executive control, and visuomotor transformation efficiency. These dynamic regulatory processes are difficult to capture using conventional paper-and-pencil or static neuropsychological assessments, underscoring the need for ecologically valid and dynamic evaluation approaches.
Virtual reality (VR), when integrated with eye-tracking and upper-limb motion analysis, enables the simulation of realistic driving environments under safe and controlled conditions. This approach facilitates precise quantification of visual search behavior, hazard detection, and visuomotor coupling, thereby offering a novel framework for cognitive assessment and driving risk prediction. Despite these advances, three critical gaps remain in the current literature: (1) a lack of systematic investigations focusing on older adults and individuals with MCI across diverse VR driving scenarios to examine visual search and attentional control; (2) artificial intelligence (AI) models that are predominantly limited to single tasks or single modalities, restricting their ability to generalize across contexts; and (3) insufficient integration of upper-limb operational data to fully characterize the dynamic interactions among vision, action, and cognition.
To address these gaps, this study adopts a multi-phase, multi-level research design. In Year 1, a VR-based eye-movement system incorporating controllable cognitive load will be developed to examine pro-saccade and anti-saccade performance among young adults, cognitively healthy older adults, and individuals with MCI. This phase will establish a high-sensitivity, eye-movement-based AI model for MCI identification. In Year 2, the framework will be extended to multi-scenario VR driving tasks through the synchronous integration of eye-tracking and upper-limb operational data, enabling characterization of visuomotor coupling under varying cognitive demands. External validation, transfer learning, and multimodal fusion techniques will be applied to enhance cross-scenario generalizability. In Year 3, multimodal datasets will be integrated to develop an explainable artificial intelligence (XAI) prediction system. Longitudinal follow-up will be conducted to evaluate its prognostic validity for changes in cognitive and driving performance, ultimately leading to a clinically applicable decision-support prototype.
At the theoretical level, this study aims to elucidate the mechanisms underlying visual attention, working memory, executive control, and visuomotor coupling in older adults and individuals with MCI under dynamic conditions. At the clinical and practical levels, it seeks to develop a non-invasive and repeatable digital cognitive screening tool for early MCI detection and older-driver risk assessment, as well as to provide evidence-based support for traffic safety policy development.
The criteria were revised on the registry on Nov 13, 2026. See what changed
The study population will include healthy young adults aged 30-39 years, as well as cognitively healthy older adults and individuals with mild cognitive impairment (MCI) aged 65-85 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy young adults (aged 30-39 years) with no history of neurological or psychiatric disorders. Participants will complete standardized virtual reality (VR) driving tasks with integrated eye-tracking and upper-limb motion recording to establish normative visuomotor and cognitive performance benchmarks.
Community-dwelling older adults (≥65 years) with normal cognitive function based on standardized screening (e.g., MoCA within normal range). Participants will undergo the same VR-based assessments to examine age-related changes in visual attention, executive control, and visuomotor coupling.
Older adults clinically identified with mild cognitive impairment according to established diagnostic criteria. Participants will complete identical VR driving tasks to investigate alterations in visual search behavior, attentional control, and visuomotor integration, and to support development of predictive AI models for cognitive decline and driving risk.
Time to First Fixation (TFF) within the Area of Interest
Time to First Fixation (TFF) is defined as the time interval from event onset (t₀) to the participant's first fixation within the predefined Area of Interest (AOI). A shorter TFF indicates faster attentional orienting. Units of Measure: milliseconds (ms) for each predefined AOI/event condition.
Time frame: Baseline
Number of Fixations on the Area of Interest
Number of Fixations is defined as the total count of fixations within the predefined Area of Interest (AOI) during task performance. A higher number of fixations indicates greater visual search activity toward target stimuli. Unit of Measure: count.
Time frame: Baseline
Total Fixation Duration (TFD) on the Area of Interest
Total Fixation Duration (TFD) is defined as the cumulative fixation time within the predefined Area of Interest (AOI) during the task. Longer fixation duration indicates greater attentional engagement with the target stimulus. Unit of measure: Milliseconds.
Time frame: Baseline
Steering Reaction Time
Steering Reaction Time is defined as the interval from event onset (t₀) to the initial steering wheel deviation of ≥5°. This measure reflects motor initiation speed during driving tasks. Steering Reaction Time will be calculated separately for each driving scenario or curve type. Unit of Measure: Milliseconds (ms).
Time frame: Baseline
Steering Reversal Rate (SRR)
Steering Reversal Rate (SRR) is defined as the number of steering direction changes per minute during curve driving, using a steering-wheel angle threshold of 0.5°. Higher SRR values indicate increased steering corrections and may reflect reduced motor control stability and increased driving workload. Unit of Measure: Reversals/minute.
Time frame: Baseline
Speed Change During Driving Tasks
Speed Change is defined as the difference in average vehicle speed before and after event onset during driving tasks. This measure reflects adaptive driving behavior in response to traffic events or environmental changes, with larger changes indicating greater speed adjustment. Speed Change will be calculated separately for each driving condition. Unit of Measure: Kilometers per hour (km/h).
Time frame: Baseline
Reaction Time in Speed-Limit Judgment Tasks
Reaction Time in Speed-Limit Judgment Tasks is defined as the elapsed time between the presentation of a speed-limit stimulus and the participant's response. This measure assesses the speed of driving-related decision-making under varying cognitive demands, with longer reaction times indicating greater cognitive processing demands. Reaction time will be calculated for each task condition. Unit of Measure: Milliseconds (ms).
Time frame: Baseline
Accuracy in Speed-Limit Judgment Tasks
Accuracy in Speed-Limit Judgment Tasks is defined as the percentage of correct responses to speed-limit judgment tasks performed during driving. This measure assesses cognitive performance under dual-task conditions, with higher accuracy indicating better task performance and cognitive processing. Accuracy will be calculated for each task condition. Unit of Measure: Percentage (%).
Time frame: Baseline
Standard Deviation of Lane Position (SDLP)
Standard Deviation of Lane Position (SDLP) is defined as the variability of the vehicle's lateral lane position during driving tasks. SDLP reflects lane-keeping ability and driving stability under different driving conditions. The lower SDLP mean better driving stability. Unit of Measure: Meters (m).
Time frame: Baseline
Frequency of Driving Errors
Driving Errors are defined as the number of adverse driving events occurring during the driving task, including lane departures, collisions, and incorrect responses to secondary tasks. This measure reflects overall driving performance and safety. Error frequencies will be calculated for each driving condition, and error types will be analyzed separately. Unit of Measure: Count.
Time frame: Baseline
Montreal Cognitive Assessment (MoCA) Score
The MoCA is used to assess global cognitive function. Participants complete a standardized set of tasks covering attention, memory, language, visuospatial abilities, and executive functions. The total MoCA score reflects overall cognitive performance.Unit of Measure: Points (0-30).
Time frame: Baseline
Digit Span Test Score
The Digit Span Test evaluates working memory capacity by requiring participants to recall sequences of numbers in forward and backward order. The highest correctly recalled sequence length is recorded separately for forward and backward trials. Unit of Measure: Number of digits correctly recalled.
Time frame: baseline
Knox Cube Test-Revised Score
The Knox Cube Test-Revised assesses visuospatial sequential memory. Participants must replicate sequences of cube taps demonstrated by the examiner. The total number of correctly recalled sequences reflects visuospatial memory performance. Unit of Measure: Number of sequences correctly recalled.
Time frame: baseline
Conners Continuous Performance Test 3 (CPT 3) Metrics
The Conners CPT 3 assesses sustained attention and inhibitory control. Primary metrics include reaction time, omission errors, commission errors, and detectability (d'). Each metric will be reported separately for each test condition. Unit of Measure: Reaction Time: milliseconds (ms); Omission Errors: count; Commission Errors: count; and Detectability (d'): unitless index.
Time frame: baseline
Started Jun 2026 (actual). Primary completion is estimated for Dec 2029, 42 months after the start.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 42 months is below that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cheng-Kung University Hospital →